Log in

NASDAQ:OXFDOxford Immunotec Global Stock Price, Forecast & News

$13.00
-0.67 (-4.90 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.94
Now: $13.00
$13.75
50-Day Range
$11.99
MA: $13.12
$13.93
52-Week Range
$8.37
Now: $13.00
$17.77
Volume220,000 shs
Average Volume109,880 shs
Market Capitalization$337.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. The company develops and markets T-SPOT.TB test used to test for tuberculosis. It is also developing C6 Borrelia burgdorferi (Lyme) ELISA kit, which measures Lyme specific antibodies; and T-SPOT.CMV test that utilizes its T-SPOT technology platform to measure the strength of a patient's cellular immune response to antigens specific to cytomegalovirus (CMV), as well as provides information for informing management strategies of patients at risk of CMV infection and disease, such as transplant patients. The company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors internationally. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Read More
Oxford Immunotec Global logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.11 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$73.71 million
Cash Flow$0.02 per share
Book Value$8.08 per share

Profitability

Net Income$-1,810,000.00

Miscellaneous

Employees215
Market Cap$337.35 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

How has Oxford Immunotec Global's stock been impacted by COVID-19 (Coronavirus)?

Oxford Immunotec Global's stock was trading at $12.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OXFD shares have increased by 6.6% and is now trading at $13.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Oxford Immunotec Global?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Oxford Immunotec Global.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Oxford Immunotec Global.

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) released its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.05. The firm had revenue of $13.91 million for the quarter, compared to analyst estimates of $14.11 million. Oxford Immunotec Global had a negative return on equity of 2.39% and a negative net margin of 8.70%. View Oxford Immunotec Global's earnings history.

What guidance has Oxford Immunotec Global issued on next quarter's earnings?

Oxford Immunotec Global issued an update on its second quarter 2020 Pre-Market earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5-6 million, compared to the consensus revenue estimate of $18.11 million.

What price target have analysts set for OXFD?

2 brokerages have issued 1-year target prices for Oxford Immunotec Global's stock. Their forecasts range from $20.00 to $20.00. On average, they expect Oxford Immunotec Global's stock price to reach $20.00 in the next year. This suggests a possible upside of 53.8% from the stock's current price. View analysts' price targets for Oxford Immunotec Global.

Has Oxford Immunotec Global been receiving favorable news coverage?

Headlines about OXFD stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a coverage optimism score of -3.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Oxford Immunotec Global.

Are investors shorting Oxford Immunotec Global?

Oxford Immunotec Global saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 564,900 shares, an increase of 6.9% from the June 15th total of 528,400 shares. Based on an average trading volume of 318,100 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.3% of the shares of the company are sold short. View Oxford Immunotec Global's Current Options Chain.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include AbbVie (ABBV), Immunomedics (IMMU), Intel (INTC), Gilead Sciences (GILD), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Dynavax Technologies (DVAX), Enterprise Products Partners (EPD) and Halozyme Therapeutics (HALO).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the following people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
  • Ms. Karen C. Koski, VP of Strategy & Investor Relations

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $13.00.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $337.35 million and generates $73.71 million in revenue each year. The company earns $-1,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is www.oxfordimmunotec.com.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]

This page was last updated on 7/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.